A citation-based method for searching scientific literature

C Berra, R Manfrini, D Regazzoli, M G Radaelli, O Disoteo, C Sommese, P Fiorina, G Ambrosio, F Folli. Pharmacol Res 2020
Times Cited: 4







List of co-cited articles
11 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
75

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
416
50

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
50

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Hiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, Cheli Melzer-Cohen, Gabriel Chodick, Kamlesh Khunti, John P H Wilding, Luis Alberto Garcia Rodriguez, Lucia Cea-Soriano, Shun Kohsaka,[...]. Lancet Diabetes Endocrinol 2020
79
50

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
99
50

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
50

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
50

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Mansoor Husain, Andreas L Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G Eliaschewitz, Denise R Franco, Ole K Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D Pedersen,[...]. N Engl J Med 2019
384
50



SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
948
25

A new equation to estimate glomerular filtration rate.
Andrew S Levey, Lesley A Stevens, Christopher H Schmid, Yaping Lucy Zhang, Alejandro F Castro, Harold I Feldman, John W Kusek, Paul Eggers, Frederick Van Lente, Tom Greene,[...]. Ann Intern Med 2009
25

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
Kåre I Birkeland, Johan Bodegard, Anna Norhammar, Josephina G Kuiper, Elena Georgiado, Wendy L Beekman-Hendriks, Marcus Thuresson, Marc Pignot, Ron M C Herings, Adriaan Kooy. Diabetes Obes Metab 2019
39
25

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
202
25

Down-regulation of miR-34a alleviates mesangial proliferation in vitro and glomerular hypertrophy in early diabetic nephropathy mice by targeting GAS1.
Le Zhang, Siyi He, Shaodong Guo, Wei Xie, Rong Xin, Hua Yu, Fan Yang, Jing Qiu, Di Zhang, Shiwen Zhou,[...]. J Diabetes Complications 2014
50
25

Dysregulation of microRNA-181b and TIMP3 is functionally involved in the pathogenesis of diabetic nephropathy.
Fu-Xiang Zhu, Heng-Lan Wu, Jian-Xiang Chen, Bin Han, Yin-Feng Guo. J Cell Physiol 2019
6
25

Metformin Regulating miR-34a Pathway to Inhibit Egr1 in Rat Mesangial Cells Cultured with High Glucose.
Can Wu, Ningning Qin, Huiwen Ren, Min Yang, Shuang Liu, Qiuyue Wang. Int J Endocrinol 2018
12
25

Liraglutide and Renal Outcomes in Type 2 Diabetes.
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
448
25

Protective effect of berberine on high glucose and hypoxia-induced apoptosis via the modulation of HIF-1α in renal tubular epithelial cells.
Xiuli Zhang, Tingwen Guan, Boxuan Yang, Zhihong Chi, Qijun Wan, Harvest F Gu. Am J Transl Res 2019
11
25

Liraglutide reduces hepatic glucolipotoxicity‑induced liver cell apoptosis through NRF2 signaling in Zucker diabetic fatty rats.
Jun Guo, Cai Li, Chunxiao Yang, Bing Li, Jie Wei, Yajun Lin, Peng Ye, Gang Hu, Jian Li. Mol Med Rep 2018
9
25


Effect of saxagliptin on the expression of HIF-1α in the liver of diabetic rats with fatty liver.
Qian Zhao, Qian Xiao, Xiangying Meng, Jianyang Chen, Weiwei Ye, Yong Zhou. Exp Ther Med 2018
3
33

FK 409 ameliorates small-for-size liver graft injury by attenuation of portal hypertension and down-regulation of Egr-1 pathway.
Kwan Man, Terence K Lee, Ting Bo Liang, Chung Mau Lo, Peter Chin-Wan Fung, Steven H Tsui, Xian Liang Li, Kevin T Ng, Sheung Tat Fan. Ann Surg 2004
58
25

Long non-coding RNA MEG3 promotes fibrosis and inflammatory response in diabetic nephropathy via miR-181a/Egr-1/TLR4 axis.
Fangfang Zha, Xiaolu Qu, Bo Tang, Ji Li, Yakun Wang, PengXi Zheng, Tingting Ji, Chun Zhu, Shoujun Bai. Aging (Albany NY) 2019
33
25

Newly diagnosed diabetes mellitus as a risk factor for serious liver disease.
Liane Porepa, Joel G Ray, Paula Sanchez-Romeu, Gillian L Booth. CMAJ 2010
67
25

Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
Jing Wu, Weiwei Tao, Dandan Bu, Yue Zhao, Tongyu Zhang, Danyang Chong, Bin Xue, Zheng Xing, Chaojun Li. FEBS Lett 2019
4
25

Ginsenoside Rg5 attenuates hepatic glucagon response via suppression of succinate-associated HIF-1α induction in HFD-fed mice.
Na Xiao, Meng-Die Lou, Yi-Tong Lu, Le-Le Yang, Qun Liu, Baolin Liu, Lian-Wen Qi, Ping Li. Diabetologia 2017
28
25

Analysis of the DNA methylation profiles of miR-9-3, miR-34a, and miR-137 promoters in patients with diabetic retinopathy and nephropathy.
Mayara Karla Dos Santos Nunes, Alexandre Sérgio Silva, Isabella Wanderley de Queiroga Evangelista, João Modesto Filho, Cecília Neta Alves Pegado Gomes, Rayner Anderson Ferreira do Nascimento, Rafaella Cristhine Pordeus Luna, Maria José de Carvalho Costa, Naila Francis Paulo de Oliveira, Darlene Camati Persuhn. J Diabetes Complications 2018
7
25

Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
C C Berra, V Resi, M Mirani, L Folini, A Rossi, S B Solerte, P Fiorina. Pharmacol Res 2020
6
25


microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles.
Kirti Bhatt, Qing-Sheng Mi, Zheng Dong. Am J Physiol Renal Physiol 2011
132
25

HIF-1 α as a Key Factor in Bile Duct Ligation-Induced Liver Fibrosis in Rats.
Joanna Moczydlowska, Wojciech Miltyk, Adam Hermanowicz, Dariusz M Lebensztejn, Jerzy A Palka, Wojciech Debek. J Invest Surg 2017
9
25

The effect of liraglutide on renal function: A randomized clinical trial.
Bernt J von Scholten, Frederik Persson, Signe Rosenlund, Peter Hovind, Jens Faber, Tine W Hansen, Peter Rossing. Diabetes Obes Metab 2017
42
25

Impact of the hypoxia-inducible factor-1 α (HIF1A) Pro582Ser polymorphism on diabetes nephropathy.
Harvest F Gu, Xiaowei Zheng, Norhashimah Abu Seman, Tianwei Gu, Ileana Ruxandra Botusan, Vivekananda Gupta Sunkari, Ezarul Faradianna Lokman, Kerstin Brismar, Sergiu-Bogdan Catrina. Diabetes Care 2013
37
25

MicroRNA-34a Promotes Renal Fibrosis by Downregulation of Klotho in Tubular Epithelial Cells.
Yong Liu, Xianjin Bi, Jiachuan Xiong, Wenhao Han, Tangli Xiao, Xinli Xu, Ke Yang, Chi Liu, Wei Jiang, Ting He,[...]. Mol Ther 2019
36
25

Pterostilbene prevents hepatocyte epithelial-mesenchymal transition in fructose-induced liver fibrosis through suppressing miR-34a/Sirt1/p53 and TGF-β1/Smads signalling.
Lin Song, Tian-Yu Chen, Xiao-Juan Zhao, Qiang Xu, Rui-Qing Jiao, Jian-Mei Li, Ling-Dong Kong. Br J Pharmacol 2019
26
25

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.
Emilie H Zobel, Bernt J von Scholten, Bryan Goldman, Frederik Persson, Tine W Hansen, Peter Rossing. Diabetes Obes Metab 2019
7
25

Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
Feng Sun, Sanbao Chai, Lishi Li, Kai Yu, Zhirong Yang, Shanshan Wu, Yuan Zhang, Linong Ji, Siyan Zhan. J Diabetes Res 2015
53
25

Diabetic nephropathy - complications and treatment.
Andy Kh Lim. Int J Nephrol Renovasc Dis 2014
213
25

Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy.
Paola Maffi, Federico Bertuzzi, Francesca De Taddeo, Paola Magistretti, Rita Nano, Paolo Fiorina, Andrea Caumo, Paolo Pozzi, Carlo Socci, Massimo Venturini,[...]. Diabetes Care 2007
51
25


Abatacept in B7-1-positive proteinuric kidney disease.
Chih-Chuan Yu, Alessia Fornoni, Astrid Weins, Samy Hakroush, Dony Maiguel, Junichiro Sageshima, Linda Chen, Gaetano Ciancio, Mohd Hafeez Faridi, Daniel Behr,[...]. N Engl J Med 2013
233
25

CNDP1, NOS3, and MnSOD Polymorphisms as Risk Factors for Diabetic Nephropathy among Type 2 Diabetic Patients in Malaysia.
Mohd Jokha Yahya, Patimah Binti Ismail, Norshariza Binti Nordin, Abdah Binti Md Akim, Wan Shaariah Binti Md Yusuf, Noor Lita Binti Adam, Nurul Fasihah Zulkifli. J Nutr Metab 2019
9
25

Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1α through mTOR-dependent pathway.
Yanling Zhao, Xiao Ma, Jiabo Wang, Yun Zhu, Ruisheng Li, Jian Wang, Xuan He, Limei Shan, Ruilin Wang, Lifu Wang,[...]. Fitoterapia 2014
30
25

Long-term acetaminophen treatment induced liver fibrosis in mice and the involvement of Egr-1.
Qingyun Bai, Hongyu Yan, Yuchen Sheng, Yao Jin, Liang Shi, Lili Ji, Zhengtao Wang. Toxicology 2017
20
25

SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53.
Duk Hoon Kim, Yu Jin Jung, Jung Eun Lee, Ae Sin Lee, Kyung Pyo Kang, Sik Lee, Sung Kwang Park, Myung Kwan Han, Sang Yong Lee, Kunga Mohan Ramkumar,[...]. Am J Physiol Renal Physiol 2011
116
25

Regulation of mice liver regeneration by early growth response-1 through the GGPPS/RAS/MAPK pathway.
Shanshan Lai, Jun Yuan, Dandan Zhao, Ning Shen, Weibo Chen, Yao Ding, Decai Yu, Jing Li, Feiyan Pan, Minsheng Zhu,[...]. Int J Biochem Cell Biol 2015
10
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.